Accomplished executive with over 15 years of US and International experience in devices, branded and generic pharmaceuticals . Extensive experience in pharmaceutical development, project management , strategic planning, in-line and global marketing. - Sales and marketing leadership roles in US and Europe. - Global brand marketing with significant cross-functional therapeutic expertise. - Leadership role in multiple global product launches. - In-line marketing responsibilities for large products.
2007 - Present
Global Marketing Director IV Delivery Systems
Lead and execute the launch of a portfolio of IV drugs contained in a new generation of delivery systems.
2005 - 2007
Global Marketing Director, Metabolic Diseases Business Unit
Global responsibility for Reductil™ / Meridia™ (anti-obesity drug). Mandated to reverse the negative sales trend of the brand. Priority on medicalization of obesity as a legitimate chronic disease.
Jan 2003 - Mar 2005
Global Marketing Director, Biologics Anti-Virals
Global responsibility for the monoclonal antibody Synagis™ (prophylaxis treatment against the RSV virus). Priority on expanding the use of the product in existing markets, launching Synagis in Japan and life cycle management. Worked in partnership with MedImmune, the US partner for the drug.
2002 - 2003
Global Marketing Director Oncology and Urology
Led the pre-launch activities for the endothelian antagonist, atrasentan (prostate cancer). Focused on identifying indications needed at launch and associated Phase III / IV trials. Secondary responsibility for the marketing of Lupron™ (prostate cancer), Hytrin (urology and CV) and Uprima™ (erectile dysfunction).
1999 - 2002
Director New Product Planning, R&D
Commercial voice in the stage gate reviews of Abbott’s drug pipeline (pre-clinical to registration) and for leading the creation of lifecycle product maps. Special focus on the biologics portfolio. Worked closely with all the Business Units of Abbott (US and International).
1996 - 1999
Global Product Manager, Diabetes Business Unit,
Responsible the global marketing of Humulin™ ($ 600 M franchise) and for the launch of Humalog™ in the US and in selected EU markets. Key priority on generating data to support the positioning of Humalog™. Responsible for providing support to the Global Business Development Team.
1996 - 1996
Manager Global Corporate Licensing
Responsible for the identification and valuation of in-licensing targets in the diabetes field. Key objective was to expand Lilly’s portfolio into the oral anti-diabetic market segment.
1994 - 1996
Manager Business Development Emerging Markets (Geneva, Switzerland)
Promoted to lead a cross functional team assisting affiliates in Eastern Europe and the Middle East to broaden their product portfolio and strengthen their local anchoring . Worked in a multi-cultural entrepreneurial environment.
1993 - 1994
Sales Manager Diabetes and Oncology , Northern Europe (Belgium)
Managed sales generated from 2 sales teams (oncology and metabolics). Product portfolio comprised of Humulin™, a BD injection devices, Euglucon ™, the blood glucose monitor Accutrend ™ (co-promotion with Boehringer Manheim), Humatrope™ and several oncology drugs. Recruited and trained team members, monitored performance and provided coaching to facilitate improvements.